Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma
Recruiting
N/A
Interventional Study
Pancreas Adenocarcinoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
At a Glance
- Age
- 18 and older
- Sex
- Any
- Study type
- Interventional
- Purpose
- Other
- Participants needed
- 10 (estimated)
- Sponsor
- Capital Health System, Inc · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The hypothesize that SBRT will limit or reverse tumor growth and thereby convert the borderline resectable disease or locally advanced disease in to a resectable tumor. Furthermore, we want to assess whether SBRT leads to an improved quality of life compared to IMRT.
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
* Able to sign the informed consent and understand the consenting process
* Completed neoadjuvant chemotherapy regimen
* Patient is 18 years of age and older
* Eastern Cooperative Oncology Group (ECOG) Status of 0-1.
* Patient has a diagnosis of Stage I to Stage III pancreatic c…
Contacts